Abstract Number: 1991 • 2016 ACR/ARHP Annual Meeting
Risk of Incident Diabetes Mellitus and Its Association with Disease-Modifying Antirheumatic Drugs and Statins in Rheumatoid Arthritis
Background/Purpose: Diabetes mellitus (DM) is an important cardiovascular risk factor in RA. Although a few prior studies reported DM risk reduction with hydroxychloroquine (HCQ) and…Abstract Number: 2077 • 2016 ACR/ARHP Annual Meeting
Impact of Diabetes, Angiotensin Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Use, and Statin Use on Presentation and Outcomes in Patients with Giant Cell Arteritis
Background/Purpose: Few retrospective studies in giant cell arteritis (GCA) previously reported, separately, that 1) patients with diabetes had less positive temporal artery biopsies (TAB), 2)…Abstract Number: 331 • 2015 ACR/ARHP Annual Meeting
Are Metabolic Factors Associated with Shoulder Osteoarthritis? a Multicentric Study.
Background/Purpose: Aging, trauma and obesity are the 3 main risk factors for knee, hip and hand osteoarthritis (OA). It is noteworthy that risk factors for…Abstract Number: 2243 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Controlled Gout, Uncontrolled Gout, and Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is caused by chronic high serum uric acid (sUA) levels (ie, hyperuricemia),…Abstract Number: 2260 • 2015 ACR/ARHP Annual Meeting
High Prevalence of Hypomagnesemia and Its Relation to BMI, Type 2 Diabetes, and Clinical Disease Measures in a VA Outpatient Rheumatology Clinic Population
Background/Purpose: Magnesium plays an essential role in multiple cellular reactions, and there is increasing interest in its role in inflammation and pain. It has been…Abstract Number: 2737 • 2015 ACR/ARHP Annual Meeting
Consistency of Treatment Effects Across Different High-Risk Clinical Phenotypes in the Tofacitinib Clinical Program
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients (pts) with RA often have comorbidities that may affect treatment response.…Abstract Number: 3116 • 2015 ACR/ARHP Annual Meeting
High Level of Inflammation Predicts the Development of Diabetes Mellitus in Patients with Psoriatic Arthritis
Background/Purpose: To estimate trends in the prevalence of diabetes mellitus (DM) in patients with psoriatic arthritis (PsA) in comparison to the general population in Ontario,…Abstract Number: 514 • 2014 ACR/ARHP Annual Meeting
Methotrexate Reduces the Frequency of Prediabetes in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Background/Purpose Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are associated with an increased risk of diabetes mellitus (DM). Disease-modifying anti-rheumatic drugs, including methotrexate (MTX), may…Abstract Number: 178 • 2014 ACR/ARHP Annual Meeting
The Effect of Initiating Pharmacologic Insulin on Serum Uric Acid Levels in Patients with Diabetes
Background/Purpose Substantial evidence links gout and hyperuricemia to diabetes. Previous studies report an association between increasing uric acid (UA) levels, insulin resistance, and type 2…Abstract Number: 169 • 2014 ACR/ARHP Annual Meeting
Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Background/Purpose: Diabetes is a well-recognized risk factor for heart disease, increasing the risk of heart disease by 2-3 fold in many studies. Recent ACC/AHA lipid…Abstract Number: 154 • 2014 ACR/ARHP Annual Meeting
Cimt in Individuals with Rheumatoid Arthritis Compared to Individuals with Type2 Diabetes
Background/Purpose It is well known that patients with RA or Type 2 diabetes (T2DM) have increased risk of atherosclerosis and CVD. Carotid ultrasound measurement of…Abstract Number: 46 • 2014 ACR/ARHP Annual Meeting
Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout
Background/Purpose: Hyperuricemia and gout are associated with an increased risk of type 2 diabetes (T2D). Xanthine oxidase inhibitors (XOI), allopurinol and febuxostat, are the main…Abstract Number: 2507 • 2014 ACR/ARHP Annual Meeting
Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret®)?
Background/Purpose 458 patients with rheumatoid arthritis (RA) and inadequate response to traditional DMARDs alone and/or TNFα blocking agents were treated with the IL-1 receptor antagonist…Abstract Number: 2306 • 2014 ACR/ARHP Annual Meeting
Quality of Care for Cardiovascular Prevention in RA: Compliance with Diabetes Screening Guidelines
Background/Purpose: Comorbidities are increasingly recognized as significant contributors of decreased quality of life, and increased mortality in RA. RA is associated with an increased risk…Abstract Number: 1276 • 2014 ACR/ARHP Annual Meeting
Hyperglycemia and Risk of Osteoarthritis
Background/Purpose Osteoarthritis (OA) is reported to be more prevalent in individuals with diabetes mellitus (DM). Potential etiologies include advanced glycation endproducts, which reduce cartilage integrity,…